Ajanta Pharma said the growth was driven by strong performance in its branded generics and US generics businesses. Revenue from branded generics in India rose 12% to ₹432 crore, while US generics revenue surged 48% to ₹344 crore.
Ajanta Pharma said the growth was driven by strong performance in its branded generics and US generics businesses. Revenue from branded generics in India rose 12% to ₹432 crore, while US generics revenue surged 48% to ₹344 crore.